Small Molecules

28 Mar 2007 Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention
28 Mar 2007 Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Metastatic Brain Cancer
28 Mar 2007 MediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
27 Mar 2007 Semafore Pharmaceuticals Initiates Phase I Clinical Trial of PI3K Inhibitor SF1126 in Solid Tumor Cancers
27 Mar 2007 Schering-Plough and Merck to Develop Another New Cholesterol Lowering Medicine
27 Mar 2007 Tekturna(R), first new type of high blood pressure medicine in a decade, provides additional blood pressure reduction when used with Diovan(R)
27 Mar 2007 Indevus Reports That Interim Review of NEBIDO(R) Phase III Data Indicates Trial Is Likely to Meet Primary Endpoints
27 Mar 2007 DiObex announces successful completion of phase 2a trial
27 Mar 2007 Ocera Therapeutics Initiates a Phase 2 Trial for Active Pouchitis
27 Mar 2007 JANUVIA(TM) Approved in the European Union for the Treatment of Type 2 Diabetes
27 Mar 2007 Momenta Pharmaceuticals Presents Preclinical Data for Novel Anticoagulant M118 At American College of Cardiology
27 Mar 2007 Clinical Data Completes Phase III Enrollment of Vilazodone for Depression
27 Mar 2007 HRA Pharma commences UK-based Phase III trial of Ella(R), a second-generation emergency contraceptive
27 Mar 2007 CombinatoRx, Incorporated (CRXX) Says Arthritis Drug Misses Primary Endpoint; Stock Falls
27 Mar 2007 Cephalon, Inc. (CEPH) Files Marketing Application for Approval of a Fentanyl Effervescent Buccal Tablet in Europe
26 Mar 2007 First Study To Show Positive Benefit On Atherosclerosis For People With Early Signs Of Diseased Arteries
26 Mar 2007 KAI Pharmaceuticals Presents Encouraging Phase 1/2 Results of a Novel Treatment for Heart Attack
25 Mar 2007 Schering-Plough's Novel Oral Thrombin Receptor Antagonist Meets Primary Endpoint in Phase II Trial
24 Mar 2007 Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
24 Mar 2007 NovaDel's European Formulation of Ondansetron Targeted for U.S. Zensana(TM)
24 Mar 2007 Hana Biosciences Provides Pipeline Update
24 Mar 2007 Advancis Pharmaceutical Corporation (AVNC) Resubmits New Drug Application for Once-Daily Amoxicillin PULSYS
23 Mar 2007 Satraplatin Phase 3 SPARC Trial - Additional Data Presented at European Association of Urology Congress
23 Mar 2007 Xanthus Initiates a Phase 1 Study of Clomet for Treatment of Solid Tumors
23 Mar 2007 Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in Japan to Merck & Co., Inc.

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up